Radioactive iodide (131 I-) excretion profiles in response to potassium iodide (KI) and ammonium perchlorate (NH4ClO4) prophylaxis.
Radioactive iodide ((131)I-) protection studies have focused primarily on the thyroid gland and disturbances in the hypothalamic-pituitary-thyroid axis. The objective of the current study was to establish (131)I- urinary excretion profiles for saline, and the thyroid protectants, potassium iodide (KI) and ammonium perchlorate over a 75 hour time-course. Rats were administered (131)I- and 3 hours later dosed with either saline, 30 mg/kg of NH(4)ClO(4) or 30 mg/kg of KI. Urinalysis of the first 36 hours of the time-course revealed that NH(4)ClO(4) treated animals excreted significantly more (131)I- compared with KI and saline treatments. A second study followed the same protocol, but thyroxine (T(4)) was administered daily over a 3 day period. During the first 6-12 hour after (131)I- dosing, rats administered NH(4)ClO(4) excreted significantly more (131)I- than the other treatment groups. T(4) treatment resulted in increased retention of radioiodide in the thyroid gland 75 hour after (131)I- administration. We speculate that the T(4) treatment related reduction in serum TSH caused a decrease synthesis and secretion of thyroid hormones resulting in greater residual radioiodide in the thyroid gland. Our findings suggest that ammonium perchlorate treatment accelerates the elimination rate of radioiodide within the first 24 to 36 hours and thus may be more effective at reducing harmful exposure to (131)I- compared to KI treatment for repeated dosing situations. Repeated dosing studies are needed to compare the effectiveness of these treatments to reduce the radioactive iodide burden of the thyroid gland.
Institute for Health Management and Mass Destruction Defense, College of Public Health, University of Georgia, Athens, GA 30603, USA. charris@ihmd.uga.edu
Curtis
C
Harris
Cham
C
Dallas
Edward
E
Rollor
Catherine
C
White
Benjamin
B
Blount
Liza
L
Valentin-Blasini
Jeffrey
J
Fisher
D000818:Animals; D007455:Iodine / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine*; D007457:Iodine Radioisotopes / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D008297:Male; D010472:Perchlorates / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D011193:Potassium Iodide / Q000627:therapeutic use*; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013959:Thyroid Diseases / Q000517:prevention & control*; D013961:Thyroid Gland / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood
D007457:Iodine Radioisotopes; D010472:Perchlorates; D000644:Quaternary Ammonium Compounds; D011193:Potassium Iodide; D013972:Thyrotropin; D007455:Iodine; C494474:perchlorate; C053506:ammonium perchlorate